SCNI stock Statistics — Scinai Immunotherapeutics Ltd. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstanding: —
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interest: —
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 52.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 52.10%
Avg volume (10D): Sign in
Avg volume (3 months)

Source: SEC filings. Information and analytics, not investment advice.

Gross marginFY Dec 25: -202.29%
Operating marginFY Dec 25: -575.29%
Net margin: —
EBITDA marginFY Dec 25: -466.90%
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -91.89%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -66.26%

Cash & equivalentsas of Dec 25: $1.66M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: $1.96M
Debt / equityas of Dec 25: 24.20%
Current ratioas of Dec 25: 1.30
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 1.09
Operating cash flowFY Dec 25: -$6.03M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -$6.05M
TTM revenue / diluted shareDiluted, FY Dec 25: 0.00